{"id":1412,"date":"1999-04-01T12:01:00","date_gmt":"1999-04-01T10:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/1999\/leserbrief-koronare-herzerkrankung-und-postmenopausale-oestrogen-gestagen-substitution-die-hers-studie"},"modified":"1999-04-01T12:01:00","modified_gmt":"1999-04-01T10:01:00","slug":"leserbrief-koronare-herzerkrankung-und-postmenopausale-oestrogen-gestagen-substitution-die-hers-studie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/1999\/leserbrief-koronare-herzerkrankung-und-postmenopausale-oestrogen-gestagen-substitution-die-hers-studie","title":{"rendered":"Leserbrief: Koronare Herzerkrankung und postmenopausale \u00d6strogen-Gestagen-Substitution. Die HERS-Studie"},"content":{"rendered":"<p>Prof. Dr. C.L. aus Ulm schreibt: Rezidive nach akuten koronaren Isch\u00e4mien sind am h\u00e4ufigsten w\u00e4hrend der ersten Monate. Insofern spricht die Laufzeit der HERS-Studie (4,1 Jahre) nicht gegen sie. Es ist aber die erste prospektive Studie dieser Art, die allerdings ein endg\u00fcltiges Urteil noch nicht erlaubt.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prof. Dr. C.L. aus Ulm schreibt: Rezidive nach akuten koronaren Isch\u00e4mien sind am h\u00e4ufigsten w\u00e4hrend der ersten Monate. Insofern spricht die Laufzeit der HERS-Studie (4,1 Jahre) nicht gegen sie. Es ist aber die erste prospektive Studie dieser Art, die allerdings ein endg\u00fcltiges Urteil noch nicht erlaubt.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[57,2481,2480,71,498,65,66],"class_list":["post-1412","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-estrogene-gestagene","tag-gestagene-oestrogene","tag-hers-studie","tag-herzinfarkt","tag-koronare-herzkrankheit","tag-myokardinfarkt","tag-oestrogene-gestagene"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1412"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1412\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}